US government more than doubles the supply of monkeypox vaccine
HHS on Friday bought 2.5 million more doses of Bavarian Nordic’s Jynneos, an FDA-licensed vaccine that’s helping to stave off this current and potentially future monkeypox outbreaks.
The order brings the total vaccine doses to be delivered in 2022 and 2023 to 4.4 million, but Bavarian said in a statement that deliveries under this contract won’t start until Q4 of 2022, and will continue through early 2023. Bavarian also said that “the majority of the doses under this contract are planned for delivery in 2023” so it won’t have any effect on the company’s financial guidance this year.
HHS has promised to deliver 296,000 doses of the Jynneos vaccine — approved to treat both smallpox and monkeypox — in the coming weeks, including 56,000 doses which will be available immediately. The US has tallied more than 300 known cases of monkeypox so far, although that number is likely an underestimate.
The Danish company also said it will produce these doses in freeze-dried form using vaccines already manufactured in bulk under an existing 10-year contract with BARDA that began in 2017. Bavarian Nordic has produced a bulk Jynneos vaccine that can make about 13 million doses for future delivery.
“While the bulk vaccine has already been invoiced, the final drug production of the vaccines (formulation, filling and freeze-drying) will occur from 2023 and onwards,” the company added.
Bavarian Nordic’s stock price has risen more than 20% in the last month.